LONDON, July 16 (UPI) -- British pharmaceutical firm GlaxoSmithKline said it would set aside $2.3 billion to cover legal costs involving two of its controversial drugs.
Investors responded positively to the news, making the assumption the $2.3 billion would be the ceiling on the firm's liabilities involving Paxil and Avandia, The New York Times reported Friday.
Earlier predictions had put the cost of the legal difficulties at $6 billion.
